Merck Serono Submits Oral Cladribine But That Doesn't End The Oral MS Race

Merck Serono's NDA filing will not prohibit a possible priority review for Novartis' oral FTY720, which had Phase III data released the same day; both applications face close scrutiny with less than ideal clinical trial packages.